NDA 075355 describes LABETALOL HYDROCHLORIDE, which is a drug marketed by Akorn Inc, Apotex Inc, Apothecon, Eurohlth Intl, Gland Pharma Ltd, Hospira, Ivax Sub Teva Pharms, Mutual Pharm, Par Form, Sandoz, Teva, and Watson Labs, and is included in fourteen NDAs. Additional details are available on the LABETALOL HYDROCHLORIDE profile page.
The generic ingredient in LABETALOL HYDROCHLORIDE is labetalol hydrochloride. There are twelve drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the labetalol hydrochloride profile page.
|Active Rx/OTC/Discontinued:||DISCN||Dosage:||INJECTABLE; INJECTION||Strength||5MG/ML|
|Approval Date:||Nov 29, 1999||TE:||RLD:||No|
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.